Welcome to the general discussion of Decibel Therapeutics advancements on Tinnitus Talk!
This company is starting to pick up momentum as of lately and myself along with many others are very excited for their advancements regarding research, drug applications targeting hearing loss, tinnitus and noise induced pain, in this general we are going to follow the company's updates to keep the forum organized.
_______________________________________________________________
Official Website, Twitter and Postal Address-
https://decibeltx.com/
https://twitter.com/decibeltx
Address: 1325 Boylston St Suite 500, Boston, MA 02215
_______________________________________________________________
Information about the company and their goals-
https://decibeltx.com/about-us/
-Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing.
-Decibel is translating cutting-edge science into hearing therapeutics to create a world in which the benefits and joys of hearing are available to all.
-Recent scientific advances, including those by Decibel's founders, have provided insights into the link between hearing dysfunction and inner ear pathology and pathogenesis. These discoveries have defined potential new therapeutic targets for the treatment of multiple types of hearing disorders. Decibel is consolidating the science, tools and technology into a unique and comprehensive hearing drug discovery and development platform, the first of its kind. Decibel will leverage this platform to discover and develop a series of breakthrough therapies targeted to specific indications with substantial unmet needs.
_______________________________________________________________
Updates-
https://decibeltx.com/news-and-events/
October 15 2015
Third Rock Ventures Launches Decibel Therapeutics with $52 Million Series A Financing to Discover New Medicines to Protect, Repair and Restore Hearing
December 16 2015
Decibel Therapeutics Appoints Jeff Jonas, M.D., CEO of SAGE Therapeutics, to its Board of Directors
July 13 2016
https://www.decibeltx.com/decibel-t...man-as-president-and-chief-executive-officer/
August 4th 2016
Decibel Therapeutics to Open New Headquarters and Laboratories in The Fenway
September 7th 2016
Decibel Therapeutics Expands Leadership Team
November 1st 2016
Decibel Therapeutics Assembles World-Class Scientific Advisory Board
January 18 2017
Decibel Therapeutics Expands Leadership Team With World-Class Bioinformatics Scientist; Appoints Three New Members to its Board of Director
February 13th 2017
Decibel Therapeutics Presents at 2017 Annual Association for Research in Otolaryngology (ARO) Meeting
May 17th 2017
Decibel Therapeutics Opens New Headquarters and The Fenway's First Lab
July 6th 2017
Decibel Therapeutics Announces Investment from GV to Expand Capabilities for Biological Target Identification in Hearing Loss and Tinnitus
November 29th 2017
Regeneron and Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus
February 9th 2018
Decibel Therapeutics Presents at 2018 Annual Association for Research in Otolaryngology (ARO) Meeting
June 19 2018
Decibel Therapeutics Closes $55 Million Series C Financing
August 2 2018
Decibel Therapeutics Research on The Role of Molecular Diversity in Neurons Critical for Hearing Published in Cell
September 27th 2018
Decibel Therapeutics and Oricula Therapeutics Announce Exclusive License for ORC-13661 in Phase 1 Development for Hearing and Balance Protection
January 7th 2019
Decibel Therapeutics and Cocoon Biotech Announce Collaboration to Develop Proprietary Formulations for Delivery of Medicines to the Inner Ear
February 5, 2019
Decibel Therapeutics Bolsters Leadership Team with Appointments of Chief Medical Officer and Chief Operating Officer
February 6, 2019
Decibel Therapeutics to Present at the Association for Research in Otolaryngology (ARO) Conference